MiniMed Group, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | $3.10B | $2.72B | $2.47B |
| Cost of Revenue | $1.42B | $1.19B | $1.03B |
| Gross Profit | $1.68B | $1.53B | $1.44B |
| Gross Margin | 54.2% | 56.3% | 58.2% |
| Operating Expenses | |||
| Research & Development | — | — | — |
| SG&A Expense | $1.18B | $1.08B | $1.06B |
| Operating Income | $-190.0M | $-146.0M | $-69.0M |
| Operating Margin | -6.1% | -5.4% | -2.8% |
| Interest Expense | — | — | — |
| Pretax Income | $-189.0M | $-147.0M | $-70.0M |
| Income Tax Expense | $128.0M | $52.0M | $38.0M |
| Net Income | $-333.0M | $-213.0M | $-112.0M |
| Net Margin | -10.7% | -7.8% | -4.5% |
| EPS (Basic) | $-1.30 | $-0.84 | $-0.44 |
| EPS (Diluted) | $-1.30 | $-0.84 | $-0.44 |
| Shares Outstanding (Basic) | 256.6M | 252.8M | 252.8M |
| Shares Outstanding (Diluted) | 256.6M | 252.8M | 252.8M |
| Dividends Per Share | — | — | — |